Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabiliseNovartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new Share XNovartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilisehttps://pharmaphorum.com/news/novartis-ceo-thinks-2nd-health-lockdown-unlikely-as-q3-sales-stabilise/
NICE changes its mind on Novartis’ Kisqali for breast cancerNICE has backed NHS use of Novartis’ CDK4/6 inhibitor Kisqali alongside fulvestrant for breast cancer patients in England Share XNICE changes its mind on Novartis’ Kisqali for breast cancerhttps://pharmaphorum.com/news/nice-changes-its-mind-on-novartis-kisqali-for-breast-cancer/
